Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Cosette Acquires Ambien® and Ambien CR® from Sanofi US
Details : Cosette Pharmaceuticals Acquires Ambien (Zolpidem Tartrate) Tablet from Sanofi US. It is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
Product Name : Ambien
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 07, 2024
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Cosette Pharma
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ambien-Generic (zolpidem tartrate) is a small molecule, GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator. It is indicated for the treatment of insomnia.
Product Name : Ambien-Generic
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 07, 2021
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sleep Satisfaction and Psychomotor Performance of Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2010
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Zolpidem in the Long-Term Treatment of Insomnia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : With this approval by Australia's TGA, ZolpiMist will be included on the Australian Register of Therapeutic Goods and will be able to be commercialized and supplied within Australia.
Product Name : Zolpimist
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 30, 2020
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2019
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase I
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2017
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase I
Sponsor : Purdue Pharmaceuticals L.P
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Validate the Questionnaire Called IDSIQâ„¢ in Patients With Insomnia Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 17, 2017
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase IV
Sponsor : Associação Fundo de Incentivo à Pesquisa
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2013
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Sponsor : Associação Fundo de Incentivo à Pesquisa
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Study Phase : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 13, 2010
Lead Product(s) : Zolpidem Tartrate
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
